De novo TBR1 variants cause a neurocognitive phenotype with ID and autistic traits: report of 25 new individuals and review of the literature.


Journal

European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235

Informations de publication

Date de publication:
06 2020
Historique:
received: 24 01 2019
accepted: 24 12 2019
revised: 26 11 2019
pubmed: 2 2 2020
medline: 28 5 2021
entrez: 2 2 2020
Statut: ppublish

Résumé

TBR1, a T-box transcription factor expressed in the cerebral cortex, regulates the expression of several candidate genes for autism spectrum disorders (ASD). Although TBR1 has been reported as a high-confidence risk gene for ASD and intellectual disability (ID) in functional and clinical reports since 2011, TBR1 has only recently been recorded as a human disease gene in the OMIM database. Currently, the neurodevelopmental disorders and structural brain anomalies associated with TBR1 variants are not well characterized. Through international data sharing, we collected data from 25 unreported individuals and compared them with data from the literature. We evaluated structural brain anomalies in seven individuals by analysis of MRI images, and compared these with anomalies observed in TBR1 mutant mice. The phenotype included ID in all individuals, associated to autistic traits in 76% of them. No recognizable facial phenotype could be identified. MRI analysis revealed a reduction of the anterior commissure and suggested new features including dysplastic hippocampus and subtle neocortical dysgenesis. This report supports the role of TBR1 in ID associated with autistic traits and suggests new structural brain malformations in humans. We hope this work will help geneticists to interpret TBR1 variants and diagnose ASD probands.

Identifiants

pubmed: 32005960
doi: 10.1038/s41431-020-0571-6
pii: 10.1038/s41431-020-0571-6
pmc: PMC7253452
doi:

Substances chimiques

T-Box Domain Proteins 0
TBR1 protein, human 0

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

770-782

Subventions

Organisme : NHGRI NIH HHS
ID : U01 HG007301
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS092339
Pays : United States
Organisme : NINDS NIH HHS
ID : K08 NS092898
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS085081
Pays : United States
Organisme : NHGRI NIH HHS
ID : UM1 HG007301
Pays : United States
Organisme : Canadian Institute of Health Research
Pays : International

Investigateurs

Shelin Adam (S)
Christèle du Souich (C)
Alison M Elliott (AM)
Anna Lehman (A)
Jill Mwenifumbo (J)
Tanya N Nelson (TN)
Clara van Karnebeek (C)
Jan M Friedman (JM)

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Bulfone A, Smiga SM, Shimamura K, Peterson A, Puelles L, Rubenstein JLR. T-brain-1: a homolog of Brachyury whose expression defines molecularly distinct domains within the cerebral cortex. Neuron. 1995;15:63–78.
doi: 10.1016/0896-6273(95)90065-9
Hevner RF, Shi L, Justice N, Hsueh YP, Sheng M, Smiga S, et al. Tbr1 regulates differentiation of the preplate and layer 6. Neuron. 2001;29:353–66.
doi: 10.1016/S0896-6273(01)00211-2
Méndez-Gómez HR1, Vergaño-Vera E, Abad JL, Bulfone A, Moratalla R, de Pablo F, et al. The T-box brain 1 (Tbr1) transcription factor inhibits astrocyte formation in the olfactory bulb and regulates neural stem cell fate. Mol Cell Neurosci. 2011;46:108–21.
doi: 10.1016/j.mcn.2010.08.011
Huang TN, Chuang HC, Chou WH, Chen CY, Wang HF, Chou SJ, et al. Tbr1 haploinsufficiency impairs amygdalar axonal projections and results in cognitive abnormality. Nat Neurosci. 2014;17:240–7.
doi: 10.1038/nn.3626
Notwell JH, Heavner WE, Darbandi SF, Katzman S, McKenna WL, Ortiz-Londono CF, et al. TBR1 regulates autism risk genes in the developing neocortex. Genome Res. 2016;26:1013–22.
doi: 10.1101/gr.203612.115
Hsueh YP, Wang TF, Yang FC, Sheng M. Nuclear translocation and transcription regulation by the membrane-associated guanylate kinase CASK/LIN-2. Nature. 2000;404:298–302.
doi: 10.1038/35005118
Hevner RF, Hodge RD, Daza RA, Englund C. Transcription factors in glutamatergic neurogenesis: conserved programs in neocortex, cerebellum, and adult hippocampus. Neurosci Res. 2006;55:223–33.
doi: 10.1016/j.neures.2006.03.004
Bedogni F, Hodge RD, Elsen GE, Nelson BR, Daza RA, Beyer RP, et al. Tbr1 regulates regional and laminar identity of postmitotic neurons in developing neocortex. Proc Natl Acad Sci USA. 2010;107:13129–34.
doi: 10.1073/pnas.1002285107
Chuang HC, Huang TN, Hsueh YP. Neuronal excitation upregulates Tbr1, a high-confidence risk gene of autism, mediating Grin2b expression in the adult brain. Front Cell Neurosci. 2014;8:280.
doi: 10.3389/fncel.2014.00280
Han W, Kwan KY, Shim S, Lam MM, Shin Y, Xu X, et al. TBR1 directly represses Fezf2 to control the laminar origin and development of the corticospinal tract. Proc Natl Acad Sci USA. 2011;108:3041–6.
doi: 10.1073/pnas.1016723108
McKenna WL, Betancourt J, Larkin KA, Abrams B, Guo C, Rubenstein JL, et al. Tbr1 and Fezf2 regulate alternate corticofugal neuronal identities during neocortical development. J Neurosci. 2011;31:549–64.
doi: 10.1523/JNEUROSCI.4131-10.2011
Magri C, Piovani G, Pilotta A, Michele T, Buzi F, Barlati S. De novo deletion of chromosome 2q24.2 region in a mentally retarded boy with muscular hypotonia. Eur J Med Genet. 2011;54:361–4.
doi: 10.1016/j.ejmg.2010.12.011
Neale BM, Kou Y, Liu L, Ma’ayan A, Samocha E, Sabo A, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 2012;485:242–5.
doi: 10.1038/nature11011
O’Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012;485:246–50.
doi: 10.1038/nature10989
O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science. 2012;338:1619–22.
doi: 10.1126/science.1227764
O’Roak BJ, Stessman HA, Boyle EA, Witherspoon KT, Martin B, Lee C, et al. Recurrent de novo mutations implicate novel genes underlying simplex autism risk. Nat Commun. 2014;5:5595.
doi: 10.1038/ncomms6595
Gilissen C, Hehir-Kwa JY, Thung DT, Witherspoon KT, Martin B, Lee C, et al. Genome sequencing identifies major causes of severe intellectual disability. Nature. 2014;511:344–7.
doi: 10.1038/nature13394
Hamdan FF, Srour M, Capo-Chichi JM, Daoud H, Nassif C, Patry L, et al. De novo mutations in moderate or severe intellectual disability. PLoS Genet. 2014;10:e1004772.
doi: 10.1371/journal.pgen.1004772
Traylor RN, Dobyns WB, Rosenfeld JA, Wheeler P, Spence JE, Bandholz AM, et al. Investigation of TBR1 hemizygosity: four individuals with 2q24 microdeletions. Mol Syndromol. 2012;3:102–12.
doi: 10.1159/000342008
Palumbo O, Fichera M, Palumbo P, Rizzo R, Mazzolla E, Cocuzza DM, et al. TBR1 is the candidate gene for intellectual disability in patients with a 2q24.2 interstitial deletion. Am J Med Genet A. 2014;164A:828–33.
doi: 10.1002/ajmg.a.36363
McDermott JH, Study DDD, Clayton-Smith J, Briggs TA. The TBR1-related autistic-spectrum-disorder phenotype and its clinical spectrum. Eur J Med Genet. 2017;17:30427–5.
Vegas N, Cavallin M, Kleefstra T, de Boer L, Philbert M, Maillard C, et al. Mutations in TBR1 gene leads to cortical malformations and intellectual disability. Eur J Med Genet. 2018;61:759–764
doi: 10.1016/j.ejmg.2018.09.012
Deriziotis P, O’Roak BJ, Graham SA, Estruch SB, Dimitropoulou D, Bernier RA, et al. De novo TBR1 mutations in sporadic autism disrupt protein functions. Nat Commun. 2014;5:4954.
Den Hoed J, Sollis E, Venselaar H, Estruch SB, Deriziotis P, Fisher SE. Functional characterization of TBR1 variants in neurodevelopmental disorder. Sci Rep. 2018;8:14279.
Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36:928–30.
doi: 10.1002/humu.22844
Tanaka AJ, Cho MT, Millan F, Juusola J, Retterer K, Joshi C, et al. Mutations in SPATA5 are associated with microcephaly, intellectual disability, seizures, and hearing loss. Am J Hum Genet. 2015;97:457–64.
doi: 10.1016/j.ajhg.2015.07.014
Thevenon J, Duffourd Y, Masurel-Paulet A, Lefebvre M, Feillet F, El Chehadeh-Djebbar S, et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test. Clin Genet. 2016;89:700–7.
doi: 10.1111/cge.12732
Yang Y, Muzny DM, Reid JG, Bainbridge MN, Willis A, Ward PA, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N. Engl J Med. 2013;369:1502–11.
doi: 10.1056/NEJMoa1306555
Tarailo-Graovac M, Shyr C, Ross CJ, Horvath GA, Salvarinova R, Ye XC, et al. Exome Sequencing and the Management of Neurometabolic Disorders. N. Engl J Med. 2016;374:2246–55.
doi: 10.1056/NEJMoa1515792
Ruggeri G, Timms AE, Cheng C, Weiss A, Kollros P, Chapman T, et al. Bi-allelic mutations of CCDC88C are a rare cause of severe congenital hydrocephalus. Am J Med Genet A. 2018;176:676–81.
doi: 10.1002/ajmg.a.38592
Bowling KM, Thompson ML, Amaral MD, Finnila CR, Hiatt SM, Engel KL, et al. Genomic diagnosis for children with intellectual disability and/or developmental delay. Genome Med. 2017;9:43.
doi: 10.1186/s13073-017-0433-1
Boyle MP, Bernard A, Thompson CL, Ng L, Boe A, Mortrud M, et al. Cell-type-specific consequences of Reelin deficiency in the mouse neocortex, hippocampus, and amygdala. J Comp Neurol. 2011;519:2061–89.
doi: 10.1002/cne.22655
Hodge RD, Kowalczyk TD, Wolf SA, Encinas JM, Rippey C, Enikolopov G, et al. Intermediate progenitors in adult hippocampal neurogenesis: Tbr2 expression and coordinate regulation of neuronal output. J Neurosci. 2008;28:3707–17.
doi: 10.1523/JNEUROSCI.4280-07.2008
Hodge RD, Garcia AJ, Elsen GE, Nelson BR, Mussar KE, Reiner SL, et al. Tbr2 expression in Cajal-Retzius cells and intermediate neuronal progenitors is required for morphogenesis of the dentate gyrus. J Neurosci. 2013;33:4165–80.
doi: 10.1523/JNEUROSCI.4185-12.2013
Ha S, Tripathi PP, Mihalas AB, Hevner RF, Beier DR. C-terminal region truncation of RELN disrupts an interaction with VLDLR, causing abnormal development of the cerebral cortex and hippocampus. J Neurosci. 2017;37:960–71.
doi: 10.1523/JNEUROSCI.1826-16.2016
Burrage LC, Eble TN, Hixson PM, Roney EK, Cheung SW, Franco LM. A mosaic 2q24.2 deletion narrows the critical region to a 0.4 Mb interval that includes TBR1, TANK, and PSMD14. Am J Med Genet A. 2013;161A:841–4.
doi: 10.1002/ajmg.a.35751
Karoglan A, Schanze D, Bär C, Muschke P, Zenker M, Schanze I. A 2q24.2 microdeletion containing TANK as novel candidate gene for intellectual disability. Am J Med Genet A. 2019;179:832–6.
doi: 10.1002/ajmg.a.61093
Nosten-Bertrand M, Kappeler C, Dinocourt C, Denis C, Germain J, Phan Dinh Tuy F, et al. Epilepsy in Dcx knockout mice associated with discrete lamination defects and enhanced excitability in the hippocampus. PLoS ONE. 2008;3:e2473.
doi: 10.1371/journal.pone.0002473

Auteurs

Sophie Nambot (S)

Centre de Génétique et Centre de Référence Maladies Rares (Anomalies du Développement de l'Interrégion Est), Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France.
Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne et Université de Bourgogne-Franche Comté, Dijon, France.

Laurence Faivre (L)

Centre de Génétique et Centre de Référence Maladies Rares (Anomalies du Développement de l'Interrégion Est), Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France.
Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne et Université de Bourgogne-Franche Comté, Dijon, France.

Ghayda Mirzaa (G)

Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA.
Department of Pediatrics, University of Washington, Seattle, WA, USA.

Julien Thevenon (J)

Centre de Génétique et Centre de Référence Maladies Rares (Anomalies du Développement de l'Interrégion Est), Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France.
Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne et Université de Bourgogne-Franche Comté, Dijon, France.
UF Innovation en diagnostic génomique des maladies rares, CHU Dijon Bourgogne, Dijon, France.

Ange-Line Bruel (AL)

Centre de Génétique et Centre de Référence Maladies Rares (Anomalies du Développement de l'Interrégion Est), Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France.
Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.
UF Innovation en diagnostic génomique des maladies rares, CHU Dijon Bourgogne, Dijon, France.

Anne-Laure Mosca-Boidron (AL)

Centre de Génétique et Centre de Référence Maladies Rares (Anomalies du Développement de l'Interrégion Est), Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France.
Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.
UF Innovation en diagnostic génomique des maladies rares, CHU Dijon Bourgogne, Dijon, France.

Alice Masurel-Paulet (A)

Centre de Génétique et Centre de Référence Maladies Rares (Anomalies du Développement de l'Interrégion Est), Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France.
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne et Université de Bourgogne-Franche Comté, Dijon, France.

Alice Goldenberg (A)

Service de génétique, CHU de Rouen, Centre Normand de Génomique Médicale et Médecine Personnalisée, Rouen, France.

Nathalie Le Meur (N)

Service de génétique, CHU de Rouen, Centre Normand de Génomique Médicale et Médecine Personnalisée, Rouen, France.

Aude Charollais (A)

Service de Pédiatrie, CHU Rouen Normandie, Rouen, France.

Cyril Mignot (C)

Service de Génétique et d'Embryologie Médicales, Hôpital Trousseau, Paris, France.

Florence Petit (F)

Clinique de Génétique Guy Fontaine, Pôle de Biologie Pathologie Génétique, Hôpital Jeanne de Flandre, CHU de Lille, F-59000, Lille, France.

Massimiliano Rossi (M)

Service de Génétique, Hospices Civils de Lyon, Centre de Recherche en Neurosciences Lyon, INSERM U1028, CNRS UMR5292, GENDEVTeam, Bron, France.

Julia Metreau (J)

Service de Neurologie Pédiatrique, Hôpital du Kremlin Bicêtre, Paris, France.

Valérie Layet (V)

Service de Génétique, Groupe Hospitalier du Havre, Le Havre, France.

Daniel Amram (D)

Unité de Génétique Médicale, CHIC de Créteil, Créteil, France.

Odile Boute-Bénéjean (O)

Clinique de Génétique Guy Fontaine, Pôle de Biologie Pathologie Génétique, Hôpital Jeanne de Flandre, CHU de Lille, F-59000, Lille, France.

Elizabeth Bhoj (E)

Department of Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Margot A Cousin (MA)

Center for Individualized Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.

Teresa M Kruisselbrink (TM)

Center for Individualized Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Department of Clinical Genomics, Mayo Clinic, Rochester, MN, 55905, USA.

Brendan C Lanpher (BC)

Center for Individualized Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Department of Clinical Genomics, Mayo Clinic, Rochester, MN, 55905, USA.

Eric W Klee (EW)

Center for Individualized Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.
Department of Clinical Genomics, Mayo Clinic, Rochester, MN, 55905, USA.

Elise Fiala (E)

Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO, USA.

Dorothy K Grange (DK)

Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO, USA.

Wendy S Meschino (WS)

Genetics Program, North York General Hospital, Toronto, ON, Canada.

Susan M Hiatt (SM)

601 Genome Way, HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.

Gregory M Cooper (GM)

601 Genome Way, HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.

Hilde Olivié (H)

Centre for Developmental Disorders, University Hospitals Leuven, Leuven, Belgium.

Wendy E Smith (WE)

Department of Pediatrics, The Barbara Bush Children's Hospital, Maine Medical Center, Portland, OR, USA.

Meghan Dumas (M)

Department of Pediatrics, The Barbara Bush Children's Hospital, Maine Medical Center, Portland, OR, USA.

Anna Lehman (A)

Department of Medical Genetics, University of British Columbia, Vancouver, BC, V6H 3N1, Canada.

Cara Inglese (C)

Department of Medical Genetics, University of British Columbia, Vancouver, BC, V6H 3N1, Canada.

Mathilde Nizon (M)

Service de Génétique Médicale, CHU de Nantes, Nantes, France.

Renzo Guerrini (R)

Neuroscience Department, Children's Hospital Meyer-University of Florence, Florence, Italy.

Annalisa Vetro (A)

Neuroscience Department, Children's Hospital Meyer-University of Florence, Florence, Italy.

Eitan S Kaplan (ES)

Department of Pediatrics, University of Washington, Seattle, WA, USA.

Dolores Miramar (D)

Genetics Unit, Biochemistry Service, Hospital Miguel Servet, Zaragoza, Spain.

Julien Van Gils (J)

Service de Génétique Médicale, CHU de Bordeaux, Bordeaux, France.

Patricia Fergelot (P)

Laboratoire de génétique moléculaire, CHU de Bordeaux, Bordeaux, France.

Olaf Bodamer (O)

Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA.

Johanna C Herkert (JC)

University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands.

Sander Pajusalu (S)

Department of Clinical Genetics, Tartu University Hospital and Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.

Katrin Õunap (K)

Department of Clinical Genetics, Tartu University Hospital and Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.

James J Filiano (JJ)

Departments of Pediatrics and Neurology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.

Thomas Smol (T)

Institut de Génétique Médicale, CHRU de Lille, Lille, France.

Amélie Piton (A)

Laboratoire de diagnostic génétique, Hôpital Civil, CHRU Strasbourg, Strasbourg, France.

Bénédicte Gérard (B)

Laboratoire de diagnostic génétique, Hôpital Civil, CHRU Strasbourg, Strasbourg, France.

Sandra Chantot-Bastaraud (S)

Service de Génétique et d'Embryologie Médicales, Hôpital Trousseau, Paris, France.
Service de Génétique et d'Embryologie Médicales, INSERM U933, Paris, France.

Thierry Bienvenu (T)

Service de génétique et biologie moléculaire, Hôpital Cochin, CHU Paris Centre, Paris, France.

Dong Li (D)

Center for Individualized Medicine, Mayo Clinic, Rochester, MN, 55905, USA.

Jane Juusola (J)

GeneDx, Gaithersburg, MD, USA.

Koen Devriendt (K)

Center for Human Genetics, University of Leuven, Leuven, Belgium.

Frederic Bilan (F)

Laboratoire de Génétique, Service de Génétique, CHU Poitiers, Poitiers, France.

Charlotte Poé (C)

Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.

Martin Chevarin (M)

Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.

Thibaud Jouan (T)

Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.

Emilie Tisserant (E)

Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.

Jean-Baptiste Rivière (JB)

Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne et Université de Bourgogne-Franche Comté, Dijon, France.
UF Innovation en diagnostic génomique des maladies rares, CHU Dijon Bourgogne, Dijon, France.

Frédéric Tran Mau-Them (F)

Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.
UF Innovation en diagnostic génomique des maladies rares, CHU Dijon Bourgogne, Dijon, France.

Christophe Philippe (C)

Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.
UF Innovation en diagnostic génomique des maladies rares, CHU Dijon Bourgogne, Dijon, France.

Yannis Duffourd (Y)

Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France.
UF Innovation en diagnostic génomique des maladies rares, CHU Dijon Bourgogne, Dijon, France.

William B Dobyns (WB)

Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA.

Robert Hevner (R)

Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA.

Christel Thauvin-Robinet (C)

Centre de Génétique et Centre de Référence Maladies Rares (Anomalies du Développement de l'Interrégion Est), Hôpital d'Enfants, CHU Dijon Bourgogne, Dijon, France. christel.thauvin@chu-dijon.fr.
Inserm UMR 1231 GAD (Génétique des Anomalies du Développement), Université de Bourgogne, Dijon, France. christel.thauvin@chu-dijon.fr.
Fédération Hospitalo-Universitaire Médecine Translationnelle et Anomalies du Développement (FHU TRANSLAD), CHU Dijon Bourgogne et Université de Bourgogne-Franche Comté, Dijon, France. christel.thauvin@chu-dijon.fr.
UF Innovation en diagnostic génomique des maladies rares, CHU Dijon Bourgogne, Dijon, France. christel.thauvin@chu-dijon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH